Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

This study has been completed.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier:
First received: February 17, 2004
Last updated: June 6, 2011
Last verified: April 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2005
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):